One article [21] reported the median OS of IDH inhibitor combination therapy in patients with newly diagnosed IDH-mutated AML and one article [29] reported the median OS of IDH inhibitor monotherapy in patients with newly diagnosed IDH-mutated AML. Here, IDH1 is linked to acute myeloid leukemia.